COMP <GO>
CNMD vs CBLL // REVENUE GROWTH (YOY)
CONMED Corporation (NYSE) VS. CeriBell Inc. (NASDAQ) • 15-METRIC TALLY: CNMD 7
— CBLL 4
▲ REVENUE GROWTH (YOY) LEADER: CBLL
LAST: $45.72 (-0.09%) • MKT CAP: $1.36B
revenue-growth
5.20%
LAST: $27.82 (+2.20%) • MKT CAP: $1.07B
revenue-growth
36.10%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CNMD VS. CBLL)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CNMD | CBLL | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 54.60% | 87.90% | -33.30 | CBLL | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 7.80% | -35.00% | +42.80 | CNMD | /roic <GO> |
| EV/EBITDA & P/E Valuation | 11.4x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 11.07% | -3.89% | +14.96 | CNMD | /fcf-yield <GO> |
| Operating Margin | 7.50% | -60.00% | +67.50 | CNMD | /operating-margins <GO> |
| Net Profit Margin | 3.40% | -60.00% | +63.40 | CNMD | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 5.20% | 36.10% | -30.90 | CBLL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.82% | 0.00% | +1.82 | CNMD | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.91 | 14.75 | -12.84 | CBLL | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 4/9 | +3.00 | CNMD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 40.6 | 54.0 | -13.44 | CBLL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.9x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.36B | $1.07B | $294.9M | CNMD | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CNMD REV | CBLL REV | CNMD GROSS % | CBLL GROSS % | CNMD FCF | CBLL FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.37B | $89.1M | 54.6% | 87.9% | $150.9M | -$41.6M |
| FY 2024 | $1.31B | $65.4M | 56.1% | 86.7% | $153.9M | -$36.4M |
| FY 2023 | $1.24B | $45.2M | — | — | $125.3M | -$29.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CNMD // BETA —
CBLL // BETA —